Breast cancer is one of the most common malignant neoplasms in women, and the incidence of breast cancer has been increasing over recent years. Her-2 positive breast cancer accounts for about 15-20 per cent of all malignant neoplasms, and there is an increasing number of drugs for HeR-2 target points. There are single anti-drugs for large molecules, such as tutos and Pattos; extracellular drugs for small molecules, such as carteini and Lapatini; and new antibodies, such as TDM-1, DS-8201. This paper presents, for example, possible adverse reactions and preventive responses during drug-to-target treatment, with the single anti-HER-2 positive breast cancer treatment. Diarrhoea. Targeting treatment drugs can stimulate gastrointestinal mucous membranes, causing abdominal pain, diarrhoea, etc. The frequency of diarrhoea is higher, especially in the early stages of drug use, and the incidence of diarrhoea is decreasing as the tolerance of the drug improves. More water is recommended for those who suffer from diarrhoea, so as to avoid fallout. Foods rich in potassium and sodium, such as bananas and oranges, are supplemented to avoid electrolyte disorders. To the extent possible, the consumption of irritating, cold and indigestionable foods should be avoided in order not to exacerbate diarrhoea. If there are serious cases of heat fever, increased pulses and decreased blood pressure during the course of the target-to-pharmaceutical treatment, timely access to the hospital is required. 2. Heart toxicity. Target treatment drugs are of a certain nature to the heart, with a small number of patients manifesting themselves as heartbreak, short-temporal, chest discomfort, and occasional heart rate disorders. Particular attention is being paid to patients with hypertension and coronary heart disease, which may be exacerbated by the targeting of medications. During the target-to-pharmaceutical treatment, it is generally recommended that the patient undergo a heart ultrasound every three months to assess the function of the heart, with particular attention to changes in the blood fraction of the heart injected. In case of mild pre-heart disorders, glycerine nitrate, musk heartballs, etc. can be administered and, in case of serious cases, can be referred to the inside. The meso-particle cell is an important cell in the human body against harmful micro-organisms such as bacteria and viruses, and a “health guard” for the human body. Although the impact of the target-to-the drug on the neutral particle cell is significantly smaller than that of chemotherapy, the target-to-the drug can be directly exposed to the neutral particle cell in the blood during the treatment, with direct lethal effects on the neutral particle cell. The reduction in the number of neutral particle cells can lead to infections caused by harmful viruses or bacteria. It is generally recommended that blood cells be reviewed every two weeks or so during the course of the target-to-pharmaceutical treatment, and that white cells be applied in a timely manner if the white cell is reduced or the neutral particle cell is reduced. Reactions such as appetite, nausea, anti-acid, vomiting, etc. The gastrointestinal response during the treatment of drugs tends to be low, with most patients suffering from mild discomfort. Targeting drugs are a certain irritation to the digestive tract and can also act as a trigger for gastrointestinal reaction in the human nervous centre. In case of discomfort, vomiting, etc., during the course of the targeted treatment, anti-optic drugs can be used to mitigate symptoms. During the treatment of drugs, patients are advised to drink more water to avoid spicy and irritating food. It is also possible to use Chinese medicine, such as acupuncture, needle pressure and Chinese medicine. In addition, studies abroad have found that lax music, muscle laxotherapy, etc. can have the effect of mitigating gastrointestinal reaction. 5. Discomfort in the form of body fatigue, inefficiency, etc. Targeting drug treatment can cause discomfort in the body, fatigue, etc., especially in the early stages of targeting treatment. For the majority of patients, fatigue tends to be moderate and to be reduced as the target is extended. For patients suffering from severe stress during the course of the target treatment, high protein diets are recommended, with as much fresh fruit and vegetables as possible; moderate in vitro aerobics can alleviate the overall discomfort caused by the target to the therapeutic drug. In addition to the adverse effects described above, there can be hair loss, rashes, allergies, etc. during the course of the drug-oriented treatment, most of which can be mitigated, and, if necessary, visit the hospital. Targets are relatively safe for therapeutic drugs and have a relatively low overall adverse effect on patients, but they also require attention and attention to prevent serious adverse effects.
Breast cancer
